Max Almond
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Max Almond has a total of 151 co-authors. Here are the top co-authors by number of shared publications:
Hugh Barr
Biophotonics Research Unit, Gloucestershire Hospitals NHS Foundation Trust, Great Western Road, Gloucester, GL1 3NN, UK
9 shared publications- James Hodson
Health Data Research, University Hospitals Birmingham NHS Foundation Trust, Birmingham, England, UK
9 shared publications - Nicholas Stone
Department of Physics and Astronomy, University of Exeter, Exeter EX4 4QL, UK
8 shared publications Anant Desai
Department of Surgery, University Hospitals Birmingham NHS Foundation Trust, Mindelsohn Way, Birmingham, B15 2TH, UK
7 shared publicationsCatherine Kendall
Biophotonics Research Unit, Gloucestershire Hospitals NHS Foundation Trust, Great Western Road, Gloucester, GL1 3NN, UK
6 shared publications- Fabio Tirotta
Department of Sarcoma and General Surgery, Midlands Abdominal and Retroperitoneal Sarcoma Unit, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK
5 shared publications
Latest Publications
- Open Access
- 26 February 2023
- Published by MDPI AG in Current Oncology
- Vol. 30 (3) , 2781-2791
Surveillance Post Surgery for Retroperitoneal Soft Tissue Sarcoma
Complete en bloc surgical resection offers the best opportunity for the cure of primary retroperitoneal sarcomas (RPS). The potential for disease recurrence, in the form of both loco-regional recurrence and distant metastases, underpins the rationale for postoperative surveillance. There is a paucity of high-quality evidence underpinning follow-up for RPS patients, and most practice guidelines draw from expert opinion and evidence from soft tissue sarcomas of the extremities. The available observational retrospective data analysis has failed to demonstrate that high-intensity radiological surveillance improves the overall survival in patients. The lack of a robust evidence base has given rise to variations in approaches to post-operative surveillance strategies adopted by specialist centres managing RPS across the world. More high-quality prospective research is needed and planned to more clearly support surveillance approaches that balance oncologic outcomes, patient-centric care, and health service value. Risk stratification tools exist and are available for use in routine practice. Their use will likely support more individualised post-operative surveillance moving forward. Surveillance will likely be underpinned by serial radiological imaging for the medium term. However, developments in genomics offer hope for biomarkers such as ctDNA to impact patient care positively in the future and further support individualised patient care pathways.
- 26 February 2023
- Published by MDPI AG in Current Oncology
- Vol. 30 (3) , 2781-2791
Open AccessSurveillance Post Surgery for Retroperitoneal Soft Tissue Sarcoma
Complete en bloc surgical resection offers the best opportunity for the cure of primary retroperitoneal sarcomas (RPS). The potential for disease recurrence, in the form of both loco-regional recurrence and distant metastases, underpins the rationale for postoperative surveillance. There is a paucity of high-quality evidence underpinning follow-up for RPS patients, and most practice guidelines draw from expert opinion and evidence from soft tissue sarcomas of the extremities. The available observational retrospective data analysis has failed to demonstrate that high-intensity radiological surveillance improves the overall survival in patients. The lack of a robust evidence base has given rise to variations in approaches to post-operative surveillance strategies adopted by specialist centres managing RPS across the world. More high-quality prospective research is needed and planned to more clearly support surveillance approaches that balance oncologic outcomes, patient-centric care, and health service value. Risk stratification tools exist and are available for use in routine practice. Their use will likely support more individualised post-operative surveillance moving forward. Surveillance will likely be underpinned by serial radiological imaging for the medium term. However, developments in genomics offer hope for biomarkers such as ctDNA to impact patient care positively in the future and further support individualised patient care pathways.
- 1 July 2021
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 47 (7) , 1763-1770
Perioperative blood transfusion is not an independent predictor for worse outcomes in retroperitoneal sarcoma surgery
- 1 July 2021
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 47 (7) , 1763-1770
Perioperative blood transfusion is not an independent predictor for worse outcomes in retroperitoneal sarcoma surgery
- 1 October 2020
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 46 (10) , 1807-1813
Liver resection for sarcoma metastases: A systematic review and experience from two European centres
- 1 October 2020
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 46 (10) , 1807-1813
Liver resection for sarcoma metastases: A systematic review and experience from two European centres
- Open Access
- 1 June 2020
- Published by Elsevier in Cancer Treatment Reviews
- Vol. 86, 102013
A review of retroperitoneal liposarcoma genomics
- 1 June 2020
- Published by Elsevier in Cancer Treatment Reviews
- Vol. 86, 102013
Open AccessA review of retroperitoneal liposarcoma genomics
- 4 May 2020
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 27 (11) , 4574-4581
Improved Biopsy Accuracy in Retroperitoneal Dedifferentiated Liposarcoma
Biopsy sensitivity in retroperitoneal dedifferentiated liposarcoma (DDLPS) is variable. Patients with grade 3 DDLPS face a significant risk of metastatic d
- 4 May 2020
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 27 (11) , 4574-4581
Improved Biopsy Accuracy in Retroperitoneal Dedifferentiated Liposarcoma
Biopsy sensitivity in retroperitoneal dedifferentiated liposarcoma (DDLPS) is variable. Patients with grade 3 DDLPS face a significant risk of metastatic d
- 1 April 2020
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 46 (4) , 706-707
Considerations on “Impact of centralisation of services on outcomes in a rare tumour: Retroperitoneal sarcomas”
- 1 April 2020
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 46 (4) , 706-707
Considerations on “Impact of centralisation of services on outcomes in a rare tumour: Retroperitoneal sarcomas”
- 24 January 2019
- Published by Oxford University Press (OUP) in British Journal of Surgery
- Vol. 106 (4) , 395-403
Diagnostic accuracy of percutaneous biopsy in retroperitoneal sarcoma
Background Percutaneous biopsy is recommended before surgery for suspected retroperitoneal sarcoma (RPS) to confirm the histological diagnosis and guide surgical strategy. The present study aimed to establish the diagnostic accuracy of percutaneous core biopsy with respect to histological diagnosis and tumour grade. Methods Data on patients with suspected RPS who underwent percutaneous biopsy followed by surgical resection between 2005 and 2016 at one of two tertiary European sarcoma units were reviewed. Histological tumour type and tumour grade on biopsy were correlated with postoperative histology to evaluate diagnostic accuracy. Results A total of 239 patients underwent percutaneous core biopsy followed by surgical resection in Milan (163, 68·2 per cent) or Birmingham (76, 31·8 per cent). Diagnostic accuracy varied with histological diagnosis (P < 0·001), but demonstrated overall concordance with final pathology following resection in 67·2 per cent of biopsies (κ = 0·606). The majority of discrepancies occurred in dedifferentiated liposarcoma (DDLPS), owing to under‐recognition of dedifferentiation in this group. Concordance between pathology on biopsy and resection improved to 81·1 per cent when DDLPS and well differentiated liposarcoma were grouped together as liposarcoma. Grade on biopsy was concordant with grade on resection specimen in 60·4 per cent of tumours (κ = 0·640). Diagnosis of high‐grade tumours on biopsy had a high specificity (98 per cent), and moderate positive predictive value (85 per cent) and negative predictive value (78 per cent). Conclusion A diagnosis of DDLPS or leiomyosarcoma on percutaneous biopsy is highly reliable. High‐grade sarcomas can be identified with high specificity, which opens the door to a study on neoadjuvant therapy in these patients.
- 24 January 2019
- Published by Oxford University Press (OUP) in British Journal of Surgery
- Vol. 106 (4) , 395-403
Diagnostic accuracy of percutaneous biopsy in retroperitoneal sarcoma
Background Percutaneous biopsy is recommended before surgery for suspected retroperitoneal sarcoma (RPS) to confirm the histological diagnosis and guide surgical strategy. The present study aimed to establish the diagnostic accuracy of percutaneous core biopsy with respect to histological diagnosis and tumour grade. Methods Data on patients with suspected RPS who underwent percutaneous biopsy followed by surgical resection between 2005 and 2016 at one of two tertiary European sarcoma units were reviewed. Histological tumour type and tumour grade on biopsy were correlated with postoperative histology to evaluate diagnostic accuracy. Results A total of 239 patients underwent percutaneous core biopsy followed by surgical resection in Milan (163, 68·2 per cent) or Birmingham (76, 31·8 per cent). Diagnostic accuracy varied with histological diagnosis (P < 0·001), but demonstrated overall concordance with final pathology following resection in 67·2 per cent of biopsies (κ = 0·606). The majority of discrepancies occurred in dedifferentiated liposarcoma (DDLPS), owing to under‐recognition of dedifferentiation in this group. Concordance between pathology on biopsy and resection improved to 81·1 per cent when DDLPS and well differentiated liposarcoma were grouped together as liposarcoma. Grade on biopsy was concordant with grade on resection specimen in 60·4 per cent of tumours (κ = 0·640). Diagnosis of high‐grade tumours on biopsy had a high specificity (98 per cent), and moderate positive predictive value (85 per cent) and negative predictive value (78 per cent). Conclusion A diagnosis of DDLPS or leiomyosarcoma on percutaneous biopsy is highly reliable. High‐grade sarcomas can be identified with high specificity, which opens the door to a study on neoadjuvant therapy in these patients.
- 1 May 2018
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 44 (5) , 571-579
Neoadjuvant and adjuvant strategies in retroperitoneal sarcoma
- 1 May 2018
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 44 (5) , 571-579
Neoadjuvant and adjuvant strategies in retroperitoneal sarcoma
- Open Access
- 1 October 2017
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 43 (10) , 1808-1815
Role of palliative resection of the primary tumour in advanced pancreatic and small intestinal neuroendocrine tumours: A systematic review and meta-analysis
- 1 October 2017
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 43 (10) , 1808-1815
Open AccessRole of palliative resection of the primary tumour in advanced pancreatic and small intestinal neuroendocrine tumours: A systematic review and meta-analysis